Related Experiment Video
Updated: Nov 22, 2025
Author Spotlight: Enhancing Nuclei Isolation for Multiome Sequencing in Challenging Tumor Microenvironments
Published on: October 13, 2023
Molecular Subtyping and Precision Medicine for Pancreatic Cancer
Fieke E M Froeling1,2, Raffaella Casolino1,3, Antonio Pea1,4
1Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK.
Abstract:
Substantial progress in recent years has dramatically increased our knowledge of the molecular basis of cancer, revealing new potential therapeutic targets and paving the way for effective personalised medicine for the treatment of many tumour types. However, pancreatic cancer has been lagging behind in this success and continues to be one of the most lethal solid malignancies. Its molecular heterogeneity and the unselected design of the majority of clinical trials to date can in part explain the reason for our failure to make a significant change in the survival outcomes for patients with pancreatic cancer. A changing paradigm in drug development is required to validate the new molecular taxonomy and to rapidly translate preclinical discovery into clinical trials. Here, we review the molecular subtyping of pancreatic cancer, the challenges in identifying effective treatment regimens according to defined low-prevalence molecular subgroups and we illustrate a new model of translational therapeutic development that was established in the U.K. (Precision-Panc) as a potentially effective solution to improve outcomes for patients with pancreatic cancer.
Insights
Pancreatic cancer remains lethal due to molecular heterogeneity. A new UK model (Precision-Panc) aims to improve patient outcomes by translating molecular discoveries into clinical trials for personalized medicine.
Area of Science:
- Oncology
- Molecular Biology
- Translational Medicine
Background:
- Cancer research has advanced molecular understanding and personalized medicine for many tumors.
- Pancreatic cancer lags behind, remaining a highly lethal malignancy with poor survival outcomes.
- Molecular heterogeneity and unselected clinical trial designs hinder progress in pancreatic cancer treatment.
Purpose of the Study:
- To review molecular subtyping of pancreatic cancer.
- To discuss challenges in developing treatments for low-prevalence molecular subgroups.
- To present a new translational therapeutic development model (Precision-Panc) for improving pancreatic cancer patient outcomes.
Main Methods:
- Review of current literature on pancreatic cancer molecular subtypes.
- Analysis of challenges in clinical trial design for rare molecular subgroups.
- Illustration of the Precision-Panc translational model.
Main Results:
- Pancreatic cancer's molecular complexity presents significant therapeutic challenges.
- Existing clinical trial approaches have not significantly improved survival rates.
- The Precision-Panc model offers a novel framework for targeted drug development and clinical validation.
Conclusions:
- A paradigm shift in drug development is necessary for pancreatic cancer.
- Validating molecular taxonomy and accelerating preclinical to clinical translation are crucial.
- The Precision-Panc initiative provides a promising solution for personalized pancreatic cancer therapy.
